The 4th ICTMC & 38th Annual Meeting of SCT

Slides:



Advertisements
Similar presentations
FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:
Advertisements

COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
Why to Randomize a Randomized Controlled Trial? (and how to do it) John Matthews University of Newcastle upon Tyne.
Experimental Design making causal inferences. Causal and Effect The IV precedes the DV in time The IV precedes the DV in time The IV and DV are correlated.
A brief introduction to randomisation methods Peter T. Donnan Professor of Epidemiology and Biostatistics.
Chapter 5 Producing Data
When Is Stratification Detrimental to a Clinical Trial Design? Part II Katherine L. Monti, Ph.D. Senior Statistical Scientist and Director of the Massachusetts.
AP Statistics Chapter 5 Notes.
Clinical Trials Hanyan Yang
What is a Clinical Trial (alpha version) John M. Harris Jr., MD President Medical Directions, Inc.
Introduction to Clinical Trials
Sampling Techniques LEARNING OBJECTIVES : After studying this module, participants will be able to : 1. Identify and define the population to be studied.
Chapter 1: The Nature of Statistics
Part III Gathering Data.
Sampling Methods. Probability Sampling Techniques Simple Random Sampling Cluster Sampling Stratified Sampling Systematic Sampling Copyright © 2012 Pearson.
Adaptive randomization
RANDOMISATION, BIAS AND BLINDING IN CLINICAL TRIALS Dipesh Mistry & Jessica Smith September 2010.
Penn CTSI Research Seminar Clinical Trials November 10, 2015 Vernon M. Chinchilli, PhD Distinguished Professor and Chair Department of Public Health Sciences.
When Is Stratification Detrimental to a Clinical Trial Design? Part I Gretchen Marcucci, M.S. Biostatistician, Rho, Inc. and Katherine L. Monti, Ph.D.
Sampling Design A population: is the entire aggregation of cases that meets a designated set of criteria.  Eligibility criteria (delimitation): the criteria.
1 Chapter 11 Understanding Randomness. 2 Why Random? What is it about chance outcomes being random that makes random selection seem fair? Two things:
3. Populations and samples Yun, Hyuk Jin. Populations Objects, or events, or procedures, or observations A population is thus an aggregate of creatures,
Outline of Stratification Lectures Definitions, examples and rationale (credibility) Implementation –Fixed allocation (permuted blocks) –Adaptive (minimization)
PRAGMATIC Study Designs: Elderly Cancer Trials
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Topic 2: Types of Statistical Studies
A New Algorithm for Unequal Allocation Randomization
A brief introduction to randomisation methods
Welcome Clinical Trials October 11, 2016 Vernon M. Chinchilli, PhD
Samples, Surveys, and Results UNIT SELF-TEST QUESTIONS
Sampling From Populations
Sampling.
Sampling and Experimentation
Chapter 7 (b) – Point Estimation and Sampling Distributions
Sampling Procedures Cs 12
Improving Adverse Drug Reaction Information in Product Labels
Sampling Population: The overall group to which the research findings are intended to apply Sampling frame: A list that contains every “element” or.
SAMPLING Purposes Representativeness “Sampling error”
Graduate School of Business Leadership
Randomized Trials: A Brief Overview
Population, Samples, and Sampling Descriptions
Meeting-6 SAMPLING DESIGN
Statistics Section 1.2 Identify different methods for selecting a sample Simulate a random process Review: quantitative and qualitative variables, population.
Sampling: Design and Procedures
Sampling: Design and Procedures
Principles of Experiment
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Randomization and Comparative Designs
Sampling: Design and Procedures
Producing Data, Randomization, and Experimental Design
Producing Data, Randomization, and Experimental Design
Elaine M Pascoe, Darsy Darssan, Liza A Vergara
Inferences and Conclusions from Data
Variables and Measurement (2.1)
Other Sampling Methods
Experimental Studies.
Into to Statistics Jeopardy
RCT Workshop, Bushehr 2/16/2019.
Ch. 7: Randomized Experiments and Causal Inference
Day 1 Parameters, Statistics, and Sampling Methods
Sampling and Power Slides by Jishnu Das.
Day 1 Parameters, Statistics, and Sampling Methods
SAMPLING AND STATISTICAL POWER
Who are the Subjects? Intro to Sampling
Chapter 7 Sampling and Sampling Distributions
HEC508 Applied Epidemiology
Considerations for the use of multiple imputation in a noninferiority trial setting Kimberly Walters, Jie Zhou, Janet Wittes, Lisa Weissfeld Joint Statistical.
2019 Joint Statistical Meetings at Denver
Presentation transcript:

The 4th ICTMC & 38th Annual Meeting of SCT Numerical Evaluation for Optimal Selection of Randomization Methods in Clinical Trials Mi Z. , Horney RA, Stock EM and Biswas K.   VA Cooperative Studies Program Coordinating Center, Perry Point/Baltimore, MD 21902

Clinical Trial Schema To study a treatment efficacy on certain disease Every individual with the disease (N) Intended Target Population Patients from participating centers during certain time Those who are interested in participating in the trial Unspecified Sampling Procedure Filtering Those who meet inclusion/exclusion criteria Unspecified Target Population Those who consent to participate the trial Targeted trial subjects ( Sample size = n) Not A Random Sample Randomization Only Random Mechanism Treatment ( nT ) Placebo ( nP ) Foundation of Causal Inferences 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

Baseline Characteristics Why Randomization Introduces random mechanism to treatment allocation Avoids selection bias to treatment allocation Balances known/unknown baseline/confounding factors between treatment arms Allows to assess treatment attributable efficacy Baseline Characteristics Category Intervention p- value Treatment Placebo Total Prognostic factor 1 Yes nT(F1) nP(F1) nF1 c1 No nT(No F1) nP(No F1) nNo F1 Prognostic factor 2 nT(F2) nP(F2) nF2 c2 nT(No F2) nP(No F2) nNo F2 Participating Sites 1 nT(S1) nP(S1) nS1 c3 2 nT(S2) nP(S2) nS2 3 nT(S3) nP(S3) nS3 4 nT(S4) nP(S4) nS4 … ... Other factors nT(OT) nP(OT) nOT c4 nT(No OT) nP(No OT) nNo OT 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Commonly Randomization Methods Simple Randomization Restricted Randomizations * Static Randomizations - Permuted Block Randomization (Fixed/Random Blocks) - Stratified Block Randomization * Dynamic Randomizations (Adaptive) - Covariate-adaptive Allocation (Minimization) - Response-adaptive Allocation 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Rationale When design a clinical trial, one task is to select an appropriate randomization method based on Sample size Treatment allocation ratio Prognostic factors need to be controlled Number of participating sites Conditions Random (no specific pattern with known probability) Balanced Unpredictable Easy to Implement Considerations 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Goal To evaluate randomization performance by simulations Simple Randomization Random Permuted Block Randomization Stratified Randomized Block Randomization Covariate-adaptive Allocation (Minimization) - Deterministic - 15% rule - 1/3 rule - Probability based on Imbalance score 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Simulation Methods Parameters Treatment Arms Two arms – Allocation 1:1 Participating Sites 5 ( 5 ~ 20, by 5) Prognostic Factors Two level-two factors: Factor 1 (0.5/0.5); Factor 2 (0.3/0.7) Sample Size 100~2000 (by 100) Simulation Replicates 10, 000 Times Algorithms Simple Randomization Randomly assign all subjects in each treatment arms based on a probability 0.5 Permuted Blocks Generate random permuted blocks (2 and 4, 4 and 6) for each treatment arm assignment Stratified Blocks Stratify prognostic factors and sites, then within each stratum generate random permuted blocks for treatment assignment Adaptive (Minimization) Balance treatment arms simultaneously over prognostic factors and sites (marginal balances based on varied conditional probability over time ) Metrics Imbalance Marginal difference between treatment arms of each controlling factors divided by sample size Average of P-values Based on Person 2 test Significance of Imbalance Based on p-value < 0.05 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Imbalance of Four Randomization Methods 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Imbalance of Minimization Methods 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Average P-Values Four Randomization Methods Minimization Methods 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Significance of Imbalance Four Randomization Methods Minimization Methods 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Example Sample size = 1520; Two treatment arms 1:1 ratio Sites = 15 Covariate = four category ( I = 15%, II = 35%, III = 30%, IV = 20%) 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Summary Imbalance decreases when sample size increases (plateau ~ 600) Stratified permuted blocks and minimization methods with lower imbalance (Imbalance: Stratified < Minimization < Permuted blocks < Simple) Minimization methods performs better when strata cells are sparse (Imbalance: Deterministic < 15% rule < 1/3 rule < Imbalance Score) Imbalance is consistent with p-values and proportion of significance (p<0.05) Tables and programs are available Contact : Zhibao.Mi@va.gov Eileen.Stock@va.gov 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Disclaimer The views expressed in this report are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or the United States Government. 9/20/2018 The 4th ICTMC & 38th Annual Meeting of SCT

The 4th ICTMC & 38th Annual Meeting of SCT Thank You